Press release
Aplastic Anemia Market to Witness Significant Growth by 2034Strategic Market Opportunities for pharma Executives | DelveInsight
Aplastic Anemia Market Insight, Epidemiology And Market Forecast - 2034
DelveInsight's "Aplastic Anemia Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding of aplastic anemia, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
According to the comprehensive analysis, the aplastic anemia market, valued at approximately USD 270 million in 2023 across the 7MM, is projected to expand substantially through 2034, fueled by increasing disease incidence, growing uptake of existing therapies, and the anticipated launch of promising pipeline candidates.
Furthermore, the US currently dominates the aplastic anemia treatment landscape, accounting for approximately 70% of the market share in the 7MM, followed by Japan with the second-highest market value at approximately USD 35 million in 2023. Among European nations, Germany leads the market, with additional growth anticipated across all regions during the forecast period.
Download the Aplastic Anemia Market Forecast Report to understand which factors are driving the Aplastic Anemia market @ Aplastic Anemia Market Trends [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
DelveInsight's aplastic anemia epidemiological analysis reveals that Japan reported the highest aplastic anemia incident cases, contributing approximately 30% of cases across the 7MM in 2023. Notably, 56% of aplastic anemia cases were reported in individuals aged 60 and above, while 43% were below the age of 60.
Discover evolving trends in the Aplastic Anemia patient pool forecasts @ Aplastic Anemia Epidemiological Analysis [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current aplastic anemia treatment varies based on patient age and disease severity. Hematopoietic stem cell transplantation (HSCT) remains the standard of care for patients under 40 years, while immunosuppressive therapy (IST) is preferred for those above 40 years. Novartis' PROMACTA / REVOLADE (eltrombopag) currently leads market revenue, followed by various immunosuppressive therapies. However, younger patients experience significantly better long-term survival compared to those aged 60 and above, highlighting a critical unmet need for improved management strategies in older populations.
The aplastic anemia therapeutic landscape is evolving with several marketed and emerging options. ALVAIZ (eltrombopag choline) from Teva Pharmaceuticals (NYSE: TEVA), an oral thrombopoietin receptor agonist that stimulates platelet production, approved in November 2023, represents an important treatment advancement. In Japan, Kyowa Kirin's ROMIPLATE has gained approval for patients showing inadequate response to conventional therapy.
The patent for PROMACTA (eltrombopag), a key treatment for aplastic anemia, is set to expire on July 13, 2025. This expiry will likely lead to the introduction of generic versions, which can reduce treatment costs and increase patient access. As Promacta is currently a leading therapy in the aplastic anemia market, the availability of generics is expected to intensify competition, lower prices, and potentially shift prescribing patterns.
Looking toward future market growth, promising pipeline candidates include REGN7257 from Regeneron Pharmaceuticals (NASDAQ: REGN), a gamma chain cytokine receptor antibody targeting the common gamma chain found in various interleukin receptors. Currently in Phase I/II clinical trials, this therapy aims to address T-cell-mediated pathogenesis in severe aplastic anemia patients who have relapsed after immunosuppressive therapy. Another noteworthy emerging therapy is OMISIRGE (omidubicel) by Gamida Cell (NASDAQ: GMDA), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood.
In April 2025, CK0801, an allogeneic T regulatory (Treg) cell therapy manufactured by Cellenkos, received FDA Orphan Drug Designation for aplastic anemia, supporting its development as a novel treatment for this rare condition. A Phase III registration trial is planned for the second half of 2025, positioning CK0801 as a promising non-immunosuppressive option for aplastic anemia patients unresponsive to standard therapies.
Discover evolving trends in the Aplastic Anemia treatment landscape @ Aplastic Anemia Recent Developments [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite therapeutic advances, significant challenges remain in the aplastic anemia treatment landscape. Finding effective and well-tolerated treatments for patients who do not respond to standard therapies or who are unsuitable candidates for aggressive interventions continues to be problematic. Additionally, poor survival rates among older patients represent a substantial unmet medical need requiring innovative approaches.
Table of Contents
1. Key Insights
2. Executive Summary of Aplastic Anemia
3. Aplastic Anemia Competitive Intelligence
4. Aplastic Anemia: Market Overview at a Glance
5. Aplastic Anemia: Disease Background and Overview
6. Patient Journey
7. Aplastic Anemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Aplastic Anemia Unmet Needs
10. Key Endpoints of Aplastic Anemia Treatment
11. Aplastic Anemia Marketed Products
12. Aplastic Anemia Emerging Therapies
13. Aplastic Anemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Aplastic Anemia
17. KOL Views
18. Aplastic Anemia Market Drivers
19. Aplastic Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Aplastic Anemia Pipeline Insight [https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Aplastic Anemia Pipeline Insight provides comprehensive insights about the Aplastic Anemia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Aplastic Anemia companies, including Gamida-Cell, Regeneron Pharmaceuticals, and BioLineRx, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aplastic-anemia-market-to-witness-significant-growth-by-2034strategic-market-opportunities-for-pharma-executives-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aplastic Anemia Market to Witness Significant Growth by 2034Strategic Market Opportunities for pharma Executives | DelveInsight here
News-ID: 4228163 • Views: …
More Releases from ABNewswire
United States Co-Working Office Space Market to Reach USD 7.38 Billion by 2030, …
Mordor Intelligence has published a new report on the United States Co-Working Office Space Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
United States Co-Working Office Space Market Overview
According to Mordor Intelligence, the US Co-Working Office Space Market size [https://www.mordorintelligence.com/industry-reports/united-states-co-working-office-space-market?utm_source=abnewswire] is estimated at USD 4.99 billion in 2025, and is expected to reach USD 7.38 billion by 2030, at a CAGR of 8.13% during the forecast period…
Reequestrian Registered Launches to Redefine Access, Affordability, and Connecti …
When Dover Saddlery abruptly closed its Pittsburgh store this September, local riders suddenly found themselves without a trusted destination for gear. Just days earlier, Reequestrian Registered had quietly opened its digital doors, - a serendipitous moment that signaled a new era for equestrian access and community.
PITTSBURGH, PA - October 16, 2025 - When Dover Saddlery abruptly closed its Pittsburgh store this September, local riders suddenly found themselves without a trusted…
Uniform Bright: The Only Firm in the World Fighting Unfair Uniform Rental Contra …
Riverside, CA - October 16, 2025 - Uniform Bright, a national consulting firm founded by industry expert Eddie Ferguson, is celebrating major wins this year in its mission to protect businesses from abusive uniform and linen rental contracts. From small restaurants to national chains, Uniform Bright has helped companies across the U.S. and now Canada to cancel unfair agreements, reduce overcharges, and challenge inflated "liquidated damages" claims.
Image: https://www.abnewswire.com/upload/2025/10/fe0793d2f5a560b52deaaad834d38e8b.PNG
"Uniform rental giants…
The Hidden Cost of Food: Why Ending Factory Farming Is Essential for the Future
In the modern world, most people rarely think about where their food comes from. The meat, milk, and eggs sitting neatly on supermarket shelves seem far removed from the vast industrial system that produces them. Yet behind the scenes, factory farming-the industrial-scale breeding and killing of animals for food-has quietly become one of the most destructive human inventions in history.
This isn't just an animal welfare issue, though the cruelty involved…
More Releases for Aplastic
Acquired Aplastic Anemia Market: Growth Trends to Watch
Acquired Aplastic Anemia Market valued at USD X.X Billion in 2024 and is projected to reach USD X.X Billion by 2032, growing at a CAGR of X.X% from 2025 to 2032.
What is the Acquired Aplastic Anemia Market and Why is It Significant?
The Acquired Aplastic Anemia market refers to the segment of healthcare focused on diagnosing, treating, and managing acquired aplastic anemia, a rare blood disorder where the bone marrow fails…
Strategic Partnerships Drive Advancements In Aplastic Anemia Treatment And Resea …
How Are the key drivers contributing to the expansion of the aplastic anemia market?
The escalating expenses on healthcare are anticipated to stimulate the aplastic anemia market's expansion in the future. This growth in healthcare spending is mainly attributed to factors like aging populations and rising chronic illnesses that necessitate expensive treatments. Investments in healthcare facilitate treatments for aplastic anemia by providing funds for specialized medical institutions, innovative therapies, and research…
Leading Element Driving Change in the Aplastic Anemia Market in 2025: Impact Of …
What Is the Estimated Market Size and Growth Rate for the Aplastic Anemia Market?
The market size of aplastic anemia has seen considerable growth in past years. There is expected growth from $6.63 billion in 2024 to $7.03 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The historic growth of this market can be credited to several factors, including a rise in the incidence of blood disorders,…
Aplastic Anemia Market: A Growing Need for Treatment
The aplastic anemia market has witnessed significant growth in recent years, driven by advancements in medical technology, increasing awareness of the condition, and the desire for effective treatment options. This post will delve into the market, exploring its size, share, opportunities, challenges, demand, and trends.
Market Size and Share
The aplastic anemia market is a substantial segment of the global hematology and oncology industry. While precise figures can vary depending on data…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Global Acquired Aplastic Anemia Market Insights, Forecast
Acquired aplastic anemia is a rare, serious blood disorder, due to failure of the bone marrow failure to produce blood cells. Bone marrow is the spongy substance found in the center of the bones of the body, in adults mainly the spine, pelvis, and large bones of the legs. The global Acquired Aplastic Anemia market is valued at xx million US$ in 2018 and will reach xx million US$ by…
